Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

By Elias Schisgall

Intel's second-quarter results well exceeded Wall Street expectations, and the company lifted its 2026 capital expenditures outlook for the year. Shares initially rallied after the bell, at one point gaining more than 10%, and were up 3.5% to $103.75 as of Thursday evening.

Deckers Outdoor's lifted its profit outlook and reported higher first-quarter sales, boosted by growth in its two biggest brands. Still, shares fell 4.8% to $91.65 in after-hours trading.

Edwards Lifesciences reported double-digit revenue growth in the second quarter and lifted the bottom end of its guidance. The stock was up 3.9% to $83.82 after the bell.

A lymphoma drug co-developed by Genmab and AbbVie failed to meet its primary endpoint in a Phase 3 trial. Genmab American Depositary Receipts fell 4% to $28.00.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 23, 2026 19:16 ET (23:16 GMT)